HE Dr Bahar Idriss Abu Garda  
Minister of Health  
Federal Ministry of Health  
PO Box 303  
Khartoum,  
The Republic of Sudan  

22 December 2017

Decision Letter: Request for 2018 Renewal of Gavi support for Pneumococcal, Pentavalent, Rotavirus, Meningococcal type A and Inactivated Polio Vaccines

Your Excellency

I am writing in relation to Sudan’s request for 2018 renewal of Gavi support to the Menengitis-A, Pneumococcal, Pentavalent and Rotavirus Vaccines, and Inactivated Polio Vaccines that was reviewed by Gavi Secretariat on 14 of December 2017.

Following the recommendations made by the Secretariat Review, I am pleased to inform you that Gavi has approved Sudan’s request, subject to several conditions and requirements as specified in the Appendices to this letter.

The Appendices include the following important information:

Appendix A: Financial and Programatic information – Support for Menengitis-A Vaccine (Men-A)  
Appendix B: Financial and Programatic information – Support for Pneumococcal Vaccine (PCV)  
Appendix C: Financial and Programatic information – Support for Pentavalent Vaccine  
Appendix D: Financial and Programatic information – Support for Rotavirus Vaccine  
Appendix E: Financial and Programatic information – Support for Inactivated Polio Vaccine  
Appendix F: Financial and Programatic information – Support for Injection Safety Devices  
Appendix G: Recommendations of the Gavi Secretariat Review

Please do not hesitate to contact my colleague Dr Rehan Hafiz at rhafiz@gavi.org if you have any questions or concerns.

Yours sincerely

Hind Khatib-Othman  
Managing Director, Country Programmes

cc: The Minister of Finance
The Director of Medical Services
Director Planning Unit, MoH
The EPI Manager
WHO Country Representative
UNICEF Country Representative
Regional Working Group
WHO HQ
UNICEF Programme Division
UNICEF Supply Division
This Decision Letter sets out the Programme Terms of a Programme.

1. **Country:** The Republic of Sudan

2. **Grant number:** 1820-SDN-28a-X / 16-SDN-08j-Y

3. **Date of Decision Letter:** 22/12/2017

4. **Date of the Partnership Framework Agreement:** 10/12/2013

5. **Programme title:** New Vaccine Support (NVS) - Meningitis A Preventive Routine

6. **Vaccine type:** Meningitis A

7. **Requested product presentation and formulation of vaccine:** Meningococcal type A, 10 doses per vial, LYOPHILISED

8. **Programme duration:** 2016 -2020

9. **Programme Budget (indicative):** (subject to the terms of the Partnership Framework Agreement)

<table>
<thead>
<tr>
<th></th>
<th>2016-2017</th>
<th>2018</th>
<th>2019</th>
<th>2020</th>
<th>Total2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Programme Budget (US$)</td>
<td>1,953,5973</td>
<td>443,000</td>
<td>1,016,000</td>
<td>1,022,000</td>
<td>4,434,597</td>
</tr>
</tbody>
</table>


11. **Indicative Annual Amounts:** (subject to the terms of the Partnership Framework Agreement)

<table>
<thead>
<tr>
<th></th>
<th>2016-2017</th>
<th>2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of Meningitis A vaccines doses</td>
<td>803,500</td>
<td></td>
</tr>
<tr>
<td>Annual Amounts (US$)</td>
<td>1,953,5975</td>
<td>443,000</td>
</tr>
</tbody>
</table>

12. **Procurement agency:** UNICEF. The Country shall release its co-financing payments each year to UNICEF.

13. **Self-procurement:** Not applicable.

14. **Co-financing obligations:** Reference code: 1820-SDN-28a-X-C

According to the co-financing policy, the Country falls within the Preparatory transition. The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.

<table>
<thead>
<tr>
<th>Type of supplies to be purchased with Country funds in each year</th>
<th>2018</th>
<th>2019</th>
<th>2020</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of vaccine doses</td>
<td>111,500</td>
<td>288,500</td>
<td>342,000</td>
</tr>
<tr>
<td>Number of AD syringes</td>
<td>39,700</td>
<td>222,600</td>
<td>263,700</td>
</tr>
<tr>
<td>Number of re-constitution syringes</td>
<td>12,300</td>
<td>31,800</td>
<td>37,600</td>
</tr>
<tr>
<td>Number of safety boxes</td>
<td>575</td>
<td>2,825</td>
<td>3,325</td>
</tr>
<tr>
<td>Value of vaccine doses (US$)</td>
<td>56,352</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total co-financing payments (US$) (including freight)</td>
<td>64,000</td>
<td>171,000</td>
<td>202,500</td>
</tr>
</tbody>
</table>

15. **Operational support for campaigns:** Not applicable.

16. **Additional reporting requirements:** Not applicable
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.

In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.

17. Financial clarifications: Not applicable.

18. Other conditions: Not applicable.

Signed by,

Hind Khatib-Othman
Managing Director, Country Programmes
22 December 2017
This Decision Letter sets out the Programme Terms of a Programme.

1. **Country:** The Republic of Sudan
2. **Grant number:** 1820-SDN-12c-X / 12-SDN-08a-Y
3. **Date of Decision Letter:** 22/12/2017
4. **Date of the Partnership Framework Agreement:** 10/12/2013
5. **Programme title:** New Vaccine Support (NVS) - Pneumococcal Routine
6. **Vaccine type:** Pneumococcal
7. **Requested product presentation and formulation of vaccine:** Pneumococcal (PCV13), 1 dose per vial, LIQUID
8. **Programme duration:** 2012-2020
9. **Programme Budget (indicative):** (subject to the terms of the Partnership Framework Agreement)
   - **Programme Budget (US$)**
     - 2012-2017: 88,290,906
     - 2018: 12,303,000
     - 2019: 16,517,500
     - 2020: 17,235,000
     - Total: 134,346,406
11. **Indicative Annual Amounts:** (subject to the terms of the Partnership Framework Agreement)
    - **Type of supplies to be purchased with Gavi funds in each year**
    - **Annual Amounts (US$)**
      - 2012-2017: 88,290,906
      - 2018: 12,303,000
12. **Procurement agency:** UNICEF. The Country shall release its co-financing payments each year to UNICEF.
13. **Self-procurement:** Not applicable.
14. **Co-financing obligations:** Reference code: 1820-SDN-12c-X-C.
    According to the co-financing policy, the Country falls within the group Preparatory transition.
    The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.
    - **Type of supplies to be purchased with Country funds in each year**
    - **Total co-financing payments (US$) (including freight)**
      - 2018: 1,726,500
      - 2019: 2,615,000
      - 2020: 3,098,000
15. **Operational support for campaigns:** Not applicable

---

6 This is the entire duration of the Programme.
7 This is the total amount endorsed by Gavi for the entire duration of the Programme.
8 This is the consolidated amount for all previous years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.
9 This is the amount that Gavi has approved.
10 This is the consolidated amount for all previously approved years. Annual amounts for 2017 onwards include only vaccine costs and freight.
16. **Additional reporting requirements:** Not applicable

<table>
<thead>
<tr>
<th>Reports and other information</th>
<th>Due dates</th>
</tr>
</thead>
<tbody>
<tr>
<td>To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.</td>
<td>15 May</td>
</tr>
<tr>
<td>In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.</td>
<td>To be agreed with Secretariat</td>
</tr>
</tbody>
</table>

17. **Financial clarifications:** Not applicable

18. **Other conditions:** Not applicable.

Signed by,

\[Signature\]

**On behalf of Gavi**
Hind Khatib-Othman
Managing Director, Country Programmes
22 December 2017
This Decision Letter sets out the Programme Terms of a Programme.

1. **Country:** The Republic of Sudan

2. **Grant number:** 1820-SDN-04a-X / 07-SDN-08-Y

3. **Date of Decision Letter:** 20/12/2017

4. **Date of the Partnership Framework Agreement:** 10/12/2013

5. **Programme title:** New Vaccine Support (NVS) - Penta-valent Routine

6. **Vaccine type:** Penta-valent

7. **Requested product presentation and formulation of vaccine:** DTP-HepB-Hib, 1 dose per vial, LIQUID

8. **Programme duration:** 2008-2020

9. **Programme Budget (indicative):** (subject to the terms of the Partnership Framework Agreement)

<table>
<thead>
<tr>
<th>Year</th>
<th>2008-2017</th>
<th>2018</th>
<th>2019</th>
<th>2020</th>
<th>Total11</th>
</tr>
</thead>
<tbody>
<tr>
<td>Programme Budget (US$)</td>
<td>95,368,21513</td>
<td>4,201,000</td>
<td>4,895,500</td>
<td>4,666,000</td>
<td>109,130,715</td>
</tr>
</tbody>
</table>


11. **Indicative Annual Amounts:** (subject to the terms of the Partnership Framework Agreement)

<table>
<thead>
<tr>
<th>Type of supplies to be purchased with Gavi funds in each year</th>
<th>2008-2017</th>
<th>2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of Penta-valent vaccines doses</td>
<td></td>
<td>3,623,100</td>
</tr>
<tr>
<td>Annual Amounts (US$)</td>
<td>95,368,21515</td>
<td>4,201,000</td>
</tr>
</tbody>
</table>

12. **Procurement agency:** UNICEF. The Country shall release its co-financing payments each year to UNICEF.

13. **Self-procurement:** No applicable.

**Co-financing obligations:** Reference code: 1820-SDN-04a-X-C

According to the co-financing policy, the Country falls within the group Preparatory transition.

The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.

<table>
<thead>
<tr>
<th>Type of supplies to be purchased with Country funds in each year</th>
<th>2018</th>
<th>2019</th>
<th>2020</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of vaccine doses</td>
<td>506,800</td>
<td>709,500</td>
<td>797,500</td>
</tr>
<tr>
<td>Number of AD syringes</td>
<td>538,800</td>
<td>758,100</td>
<td>851,800</td>
</tr>
<tr>
<td>Number of safety boxes</td>
<td>5,950</td>
<td>8,350</td>
<td>9,375</td>
</tr>
<tr>
<td>Value of vaccine doses (US$)</td>
<td>547,294</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total co-financing payments (US$) (including freight)</td>
<td>612,000</td>
<td>836,000</td>
<td>939,500</td>
</tr>
</tbody>
</table>

14. **Operational support for campaigns:** Not applicable

---

11 This is the entire duration of the Programme.
12 This is the total amount endorsed by Gavi for the entire duration of the Programme.
13 This is the consolidated amount for all previous years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.
14 This is the amount that Gavi has approved.
15 This is the consolidated amount for all previously approved years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.
15. **Additional reporting requirements**: Not applicable

<table>
<thead>
<tr>
<th>Reports and other information</th>
<th>Due dates</th>
</tr>
</thead>
<tbody>
<tr>
<td>To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.</td>
<td>15 May</td>
</tr>
<tr>
<td>In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.</td>
<td>To be agreed with Secretariat</td>
</tr>
</tbody>
</table>

16. **Financial clarifications**: Not applicable.

17. **Other conditions**: Not applicable.

Signed by,

Hind Khatib
Managing Director, Country Programmes
22 December 2017
This Decision Letter sets out the Programme Terms of a Programme.

1. **Country:** The Republic of Sudan

2. **Grant number:** 1820-SDN-13b-X / 10-SDN-08b-Y

3. **Date of Decision Letter:** 22/12/2017

4. **Date of the Partnership Framework Agreement:** 10/12/2013

5. **Programme title:** New Vaccine Support (NVS) - Rotavirus Routine

6. **Vaccine type:** Rotavirus

7. **Requested product presentation and formulation of vaccine:** Rotavirus, 2 doses schedule

8. **Programme duration:** 2011 -2020

9. **Programme Budget (indicative):** (subject to the terms of the Partnership Framework Agreement)

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Programme Budget (US$)</td>
<td>35,464,718¹⁸</td>
<td>4,453,500</td>
<td>5,713,500</td>
<td>5,725,500</td>
<td>51,357,218</td>
</tr>
</tbody>
</table>


11. **Indicative Annual Amounts:** (subject to the terms of the Partnership Framework Agreement)¹⁹

<table>
<thead>
<tr>
<th>Type of supplies to be purchased with Gavi funds in each year</th>
<th>2011-2017</th>
<th>2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of Rotavirus vaccines doses</td>
<td></td>
<td>2,143,500</td>
</tr>
<tr>
<td>Annual Amounts (US$)</td>
<td>35,464,718²⁰</td>
<td>4,453,500</td>
</tr>
</tbody>
</table>

12. **Procurement agency:** UNICEF. The Country shall release its co-financing payments each year to UNICEF.

13. **Self-procurement:** Not applicable.

14. **Co-financing obligations:** Reference code: 1820-SDN-13b-X-C.

   According to the co-financing policy, the Country falls within the group Preparatory transition. The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.

<table>
<thead>
<tr>
<th>Type of supplies to be purchased with Country funds in each year</th>
<th>2018</th>
<th>2019</th>
<th>2020</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of vaccine doses</td>
<td>328,500</td>
<td>496,500</td>
<td>588,000</td>
</tr>
<tr>
<td>Value of vaccine doses (US$)</td>
<td>660,619</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total co-financing payments (US$) (including freight)</td>
<td>682,500</td>
<td>1,030,500</td>
<td>1,221,000</td>
</tr>
</tbody>
</table>

15. **Operational support for campaigns:** Not applicable

16. **Additional reporting requirements:** Not applicable

---

¹⁶ This is the entire duration of the Programme.
¹⁷ This is the total amount endorsed by Gavi for the entire duration of the Programme.
¹⁸ This is the consolidated amount for all previous years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.
¹⁹ This is the amount that Gavi has approved.
²⁰ This is the consolidated amount for all previously approved years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.
Reports and other information | Due dates
---|---
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received. | 15 May
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance. | To be agreed with Secretariat

17. Financial clarifications: Not applicable.

18. Other conditions: Not applicable

Signed by,

On behalf of Gavi
Hind Khatib-Othman
Managing Director, Country Programmes
20 December 2017
### Decision Letter

**Sudan - Support for Inactivated Polio Vaccine (IPV)**

This Decision Letter sets out the Programme Terms of a Programme.

1. **Country:** The Republic of Sudan

2. **Grant number(s):** 1518-SDN-25c-X / 15-SDN-08h-Y

3. **Date of Decision Letter:** 22/12/2017

4. **Date of the Partnership Framework Agreement:** 10/12/2013

5. **Programme title:** New Vaccine Support (NVS), IPV routine

6. **Vaccine type:** Inactivated Polio Vaccine (IPV)

7. **Requested product presentation and formulation of vaccine:** Inactivated Polio Vaccine, 10 doses per vial, LIQUID

8. **Programme duration:** 2015 - 2018

9. **Indicative Programme Budget:** (subject to the terms of the Partnership Framework Agreement)

   Please note that endorsed or approved amounts for 2019 will be communicated in due course, taking into account updated information on country requirements and following Gavi’s review and approval processes.

<table>
<thead>
<tr>
<th></th>
<th>2015-2017</th>
<th>2018</th>
<th>Total(^{23})</th>
</tr>
</thead>
<tbody>
<tr>
<td>Routine Programme (US$)</td>
<td>2,104,492(^{24})</td>
<td>1,346,000</td>
<td>3,450,492</td>
</tr>
<tr>
<td>Catch-up vaccination (US$)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Total Budget (US$)</strong></td>
<td>2,104,492</td>
<td>1,346,000</td>
<td>3,450,492</td>
</tr>
</tbody>
</table>

10. **Vaccine introduction grant:** US$1,040,500 disbursed on 10 November 2014 as per Decision Letter dated 4 August 2014.

11. **Indicative Annual Amounts:** (subject to the terms of the Partnership Framework Agreement)\(^{25}\)

<table>
<thead>
<tr>
<th>Number of vaccines to be purchased with Gavi funds</th>
<th>2015-2017</th>
<th>2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>IPV Routine Programme (doses)</td>
<td></td>
<td>1,622,900</td>
</tr>
<tr>
<td>IPV Catch-up vaccination (doses)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Annual Amounts (US$)</strong></td>
<td>2,104,492</td>
<td>1,346,000</td>
</tr>
</tbody>
</table>

12. **Procurement agency:** UNICEF.

13. **Self-procurement:** Not applicable.

14. **Co-financing obligations:** Not applicable

   Gavi’s usual co-financing requirements do not apply to IPV. However, Sudan is encouraged to contribute to vaccine and/or supply costs for IPV.

15. **Operational support for catch-up campaigns:** Not applicable

16. **Additional reporting requirements:**

<table>
<thead>
<tr>
<th>Reports and other information</th>
<th>Due dates</th>
</tr>
</thead>
<tbody>
<tr>
<td>To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed program activities</td>
<td>15 May</td>
</tr>
</tbody>
</table>

---

\(^{21}\) Please refer to section 18 for additional information on IPV presentation.

\(^{22}\) This is the entire duration of the Programme.

\(^{23}\) This is the total amount endorsed by Gavi for 2015 to 2018.

\(^{24}\) This is the consolidated amount for all previous years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

\(^{25}\) This is the amount that Gavi has approved.
<table>
<thead>
<tr>
<th>Changes in presentation or minimum co-financing levels and vaccines received.</th>
<th>To be agreed with Secretariat</th>
</tr>
</thead>
<tbody>
<tr>
<td>In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.</td>
<td></td>
</tr>
</tbody>
</table>

### 17. Financial clarifications:
Not applicable.

### 18. Other conditions:
Not applicable

Due to unprecedented demand for IPV and the challenges to scale up production capacities, the global IPV supply remains constrained and is unlikely to meet all country requirements in the short term. As a consequence, the actual presentation and number of doses shipped may differ from those specified in this Decision Letter. In order to mitigate these circumstances, you are strongly encouraged to optimally manage available supply and follow recommendations and guidelines from WHO and UNICEF to reduce vaccine wastage.

If Sudan envisages a switch in product presentation, it is encouraged to incorporate elements for both IPV presentations in your initial introduction preparations, in order to minimise the need for later interventions and facilitate the switch. In those circumstances, in principle, no product switch grant will be provided to Sudan.

Signed by,

[Signature]

**On behalf of Gavi**

Hind Khatib-Othman  
Managing Director, Country Programmes  
22 December 2017
Decision Letter
Sudan - Support for Injection safety devices

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: The Republic of Sudan
2. Grant number: 17-SDN-32a-X; 18-SDN-32a-X; 19-SDN-32a-X; 20-SDN-32a-X
3. Date of Decision Letter: 22/12/2017
4. Date of the Partnership Framework Agreement: 10/12/2013
5. Programme title: Injection Safety Devices
6. Programme duration: 2017-2020

7. Programme Budget (indicative): (subject to the terms of the partnership framework agreement)

<table>
<thead>
<tr>
<th></th>
<th>2017</th>
<th>2018</th>
<th>2019</th>
<th>2020</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Programme Budget (US$)</td>
<td>457,652</td>
<td>382,500</td>
<td>487,500</td>
<td>478,500</td>
<td>1,806,152</td>
</tr>
</tbody>
</table>

8. Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement)

<table>
<thead>
<tr>
<th>Injection safety devices to be purchased with Gavi funds in each year</th>
<th>2017</th>
<th>2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of AD syringes</td>
<td>8,324,200</td>
<td></td>
</tr>
<tr>
<td>Number of re-constitution syringes</td>
<td>88,500</td>
<td></td>
</tr>
<tr>
<td>Number of safety boxes</td>
<td>92,575</td>
<td></td>
</tr>
<tr>
<td><strong>Total Annual Amounts for injection safety devices for all Gavi vaccines (US$)</strong></td>
<td>457,652</td>
<td>382,500</td>
</tr>
</tbody>
</table>

Injection safety devices to be purchased with Gavi funds in each year, by type of support

**New Vaccine Support (NVS), Pneumococcal (PCV13), 1 dose per vial LIQUID, Routine**

- Number of AD syringes: 3,423,600
- Number of safety boxes: 37,675
- **Total Annual Amounts for injection safety devices for Vaccine (US$):** 155,500

**New Vaccine Support (NVS), DTP-HepB-Hib, 1 dose per vial, LIQUID**

- Number of AD syringes: 3,852,000
- Number of safety boxes: 42,375
- **Total Annual Amounts for injection safety devices for Vaccine (US$):** 174,500

**New Vaccine Support (NVS), Inactivated Polio Vaccine, 10 doses per vial, LIQUID, Routine**

- Number of AD syringes: 761,700

---

26 This does not include vaccines.
27 This is the entire duration of the Programme.
28 This is the total amount endorsed by Gavi for the entire duration of the Programme.
29 This is the amount that Gavi has approved.
<table>
<thead>
<tr>
<th>Number of safety boxes</th>
<th>8,375</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Annual Amounts for injection safety devices for Vaccine (US$)</strong></td>
<td>34,500</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>New Vaccine Support (NVS), Meningococcal type A, 10 doses per vial, LYOPHILISED, Routine</th>
<th>2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of AD syringes</td>
<td>286,900</td>
</tr>
<tr>
<td>Number of re-constitution syringes</td>
<td>88,500</td>
</tr>
<tr>
<td>Number of safety boxes</td>
<td>4,150</td>
</tr>
<tr>
<td><strong>Annual Amounts for injection safety devices for Vaccine (US$)</strong></td>
<td>18,000</td>
</tr>
</tbody>
</table>

9. **Procurement agency**: UNICEF. The Country shall release its co-financing payments each year to UNICEF.

10. **Self-procurement**: Not applicable.

11. **Co-financing obligations**: Co-financing requirements are listed in the relevant vaccine Decision Letter.

Signed by,

On behalf of Gavi
Hind Khatib-Othman
Managing Director, Country Programmes
22 December 2017
Appendix G

Gavi Secretariat Review Recommendations

The Secretariat Review, following its deliberations:

- Urged the country to ensure that immunisation activities reach all regions, including Darfur;

- The approval of the 2017 tranche of HSS funds will be postponed to 2018 until the country has re-imbursed the US$ 4,869 of unsupported expenditures identified in Gavi Programme Audit in 2016 and committed to be repaid to Gavi by the end of 2017;

- Encouraged the country to complete the implementation of activities agreed in the audit action plan with high priority to the construction, procurement and incentives related activities;

- Encouraged the country to expedite the finalisation of the workplan budget of the relocation exercise to ensure a faster implementation of the HSS and Performance Payment activities;

- Encouraged the country to urgently finalize pending clarification to the Measles follow up campaign and Yellow Fever.